Relmada Therapeutics (RLMD) Total Liabilities (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Total Liabilities data on file, last reported at $16.6 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 217.44% year-over-year to $16.6 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 217.44% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, down 27.24% from the prior year.
• Total Liabilities for Q1 2026 stood at $16.6 million, up from $7.5 million in the prior quarter.
• Over the last five years, Total Liabilities for RLMD reached as high as $215.8 million in Q2 2022 and fell as low as $5.2 million in Q2 2025.
• Historically, Total Liabilities has averaged $48.6 million across 5 years, with a median of $12.4 million in 2024.
• Across the five-year window, Total Liabilities sank 92.73% in 2025 and jumped 217.44% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $12.5 million in 2022, then slipped by 2.2% to $12.2 million in 2023, then decreased by 15.57% to $10.3 million in 2024, then dropped by 27.24% to $7.5 million in 2025, then surged by 121.99% to $16.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $16.6 million in Q1 2026, $7.5 million in Q4 2025, and $5.4 million in Q3 2025.